CD8A and congenital rubella syndrome: Furthermore, CD8‐LVs are used to generate in vivo CAR‐T‐induced CRS,[98] similar to what occurs in patients treated with CAR‐T immunotherapy in the clinic.[115] Accordingly, more deeply studying the mechanisms of insertional mutagenesis specific to intrinsic target sites[116] and performing clinical trials on in vivo CAR‐T therapy might improve the prediction and management of adverse events.